Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 5
2014 2
2015 10
2016 16
2017 13
2018 10
2019 9
2020 8
2021 7
2022 5
2023 15
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial.
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Kurozumi A, Hatazaki M, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ryomoto K, Kato K, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I; UTOPIA study investigators. Katakami N, et al. Among authors: kurozumi a. Cardiovasc Diabetol. 2023 Jun 22;22(1):143. doi: 10.1186/s12933-023-01879-4. Cardiovasc Diabetol. 2023. PMID: 37349722 Free PMC article. Clinical Trial.
Continuous glucose monitoring-derived time in range and CV are associated with altered tissue characteristics of the carotid artery wall in people with type 2 diabetes.
Mita T, Katakami N, Okada Y, Yoshii H, Osonoi T, Nishida K, Shiraiwa T, Kurozumi A, Taya N, Wakasugi S, Sato F, Ishii R, Gosho M, Shimomura I, Watada H. Mita T, et al. Among authors: kurozumi a. Diabetologia. 2023 Dec;66(12):2356-2367. doi: 10.1007/s00125-023-06013-3. Epub 2023 Sep 26. Diabetologia. 2023. PMID: 37750893 Free PMC article.
Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial.
Tanaka A, Sata M, Okada Y, Teragawa H, Eguchi K, Shimabukuro M, Taguchi I, Matsunaga K, Kanzaki Y, Yoshida H, Ishizu T, Ueda S, Kitakaze M, Murohara T, Node K; PROTECT study investigators. Tanaka A, et al. Eur Heart J Cardiovasc Pharmacother. 2023 Feb 2;9(2):165-172. doi: 10.1093/ehjcvp/pvac059. Eur Heart J Cardiovasc Pharmacother. 2023. PMID: 36308299 Free PMC article. Clinical Trial.
Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: A randomized clinical trial (PROCEED).
Tanaka A, Okada Y, Torimoto K, Kamei N, Hirai H, Kono T, Sugimoto K, Teragawa H, Taguchi I, Maruhashi T, Sonoda S, Kurozumi A, Inagaki S, Oshita C, Hisauchi I, Takahashi K, Higashi Y, Shimabukuro M, Node K; PROCEED Trial Investigators. Tanaka A, et al. Among authors: kurozumi a. Diabetes Metab. 2023 Jul;49(4):101447. doi: 10.1016/j.diabet.2023.101447. Epub 2023 Apr 26. Diabetes Metab. 2023. PMID: 37116858 Clinical Trial. No abstract available.
89 results